🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — July 2024 Page 6

NNT for MACE prevention — July 2024

gary_naperville Tue, Dec 17, 2024 at 10:59 AM 36 replies 1,910 viewsPage 6 of 8
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Dec 23, 2024 at 9:44 PM#26
HPLC_Greg said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely!
HPLC_Greg said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

Last edited: Dec 24, 2024 at 3:44 AM
4 2Dr.LipidDallas, alex_tucson, kevin_tulsa and 1 other
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Dec 24, 2024 at 12:13 PM#27
HPLC_Greg said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off lisinopril entirely!

That reframing is the part I needed. Taking it to my next appointment.

5 3NeuroNate, JessicaH_TX, KevinCompounds and 2 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Dec 25, 2024 at 2:42 AM#28

Clinical perspective, offered as context rather than as advice.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 7.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 3.5 mg/L (moderate risk)
Month 12 hsCRP: 0.3 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 14% to 6%. My cardiologist is genuinely impressed.

6 4LindaRN_retired, tommy_boulder, hyun_seoul and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Dec 25, 2024 at 5:11 PM#29
Dr.PeteFamMed said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

This matches mine closely enough to be worth saying so out loud.

7 5RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 4 others
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Dec 26, 2024 at 7:39 AM#30
Dr.PeteFamMed said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 11 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 50" → 36" ✅ Resolved
  2. Triglycerides: 222 → 97 ✅ Resolved
  3. HDL: 34 → 54 ✅ Resolved
  4. Blood pressure: 142/96 → 120/74 ✅ Resolved
  5. Fasting glucose: 117 → 86 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

29 2RickReta_CO, PharmHunterJen, TomTeleRx and 26 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register